Given FGF13’s association with diabetic neuropathy in mouse models (50) and that altered FGF13 expression has been observed in patients with T2DN (51), we evaluated in vivo efficacy of PW164 in the T2DN HFD model. This evidence concerns the gene FGF13 and diabetic neuropathy.